Emcure Pharmaceuticals Peer Comparison

NSE: EMCURE | BSE: 544210

₹1,770.40

₹-12.20 (-0.68%)

As on 23-Oct-2026IST

Market cap

₹33,547 Cr

Revenue (TTM)

₹9,683 Cr

P/E Ratio

33.2

P/B Ratio

6.4

Div. Yield

0.2 %

Edit

	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech	Sudeep Pharma
Market cap (₹ Cr)	33,547	24,280	15,313	12,856	10,890
Revenue (₹ Cr)	9,683	2,372	2,590	1,108	676
Net Profit (₹ Cr)	1,018.97	497.77	603.02	270.18	183.60
Net Margin (%)	10.47	20.72	22.63	23.29	26.06
RoE (%)	21.30	28.49	19.61	14.45	22.72
Price to Earnings	33.17	48.78	25.39	46.68	59.63
Price-To-Book	6.41	12.01	4.39	6.20	11.79

Income Statement (₹ Cr)

	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech	Sudeep Pharma
Operating Revenue	9,683.45	2,371.81	2,590.40	1,108.39	675.61
Total Income	9,730.84	2,402.61	2,664.23	1,159.90	704.48
Total Expenditure	7,739.53	1,608.91	1,753.71	720.01	442.67
EBITDA	1,943.92	762.90	836.69	388.38	232.94
Depreciation	425.10	98.11	78.88	74.78	15.56
EBIT	1,518.82	664.79	757.81	313.60	217.38
Interest	148.45	26.33	5.43	0.26	7.96
Other Income	47.39	30.80	73.83	51.50	28.87
Exceptional Items	-27.85	0.00	-25.66	-3.28	0.00
Profit before Tax	1,389.91	669.26	800.55	361.56	238.30
Provision for Tax	370.94	171.48	197.53	91.39	54.69
Profit after Tax	1,018.97	497.77	603.02	270.18	183.60

	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech	Sudeep Pharma
Shareholder's Funds	4,950.03	1,874.47	3,332.13	2,017.06	883.34
Minority Interest	-7.58	0.00	0.00	2.51	-0.97
Non-Current Liabilities	723.57	345.47	142.73	50.51	74.82
Current Liabilities	3,912.24	710.20	508.04	169.08	201.96
Total Liabilities	9,514.48	2,930.14	4,157.10	2,231.79	1,174.38

	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech	Sudeep Pharma
Non-Current Assets	3,392.16	1,290.62	1,321.38	957.22	477.92
Current Assets	5,612.10	1,483.13	2,649.36	1,250.11	623.97
Total Assets	9,514.48	2,930.14	4,157.10	2,231.79	1,174.38
Total Debt*	1,204.08	196.61	0.00	0.00	148.29
Net Current Assets	1,699.86	772.93	2,141.33	1,081.04	422.01
Contingent Liabilities	258.92	13.18	4.82	3.76	--

	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech	Sudeep Pharma
Cash From Operating Activities	943.55	346.68	565.41	266.88	69.55
Cash Flow from Investing Activities	-1,193.06	-423.73	-570.15	-142.72	-330.93
Cash from Financing Activities	343.43	20.98	-64.34	-112.88	247.29
Net Cash Inflow / Outflow	93.92	-56.08	-69.08	11.28	-14.09

	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech	Sudeep Pharma
ROCE (%)	25.25	27.50	24.61	18.04	28.50
ROE (%)	21.30	28.49	19.61	14.45	22.72
ROA (%)	11.42	19.48	16.31	12.66	31.25
EBIT Margin (%)	15.68	28.03	29.25	28.29	32.18
Net Margin (%)	10.47	20.72	22.63	23.29	26.06
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech	Sudeep Pharma
Revenue Growth (%)	18.36	78.33	7.93	-6.72	23.56
EBIT Growth (%)	30.43	303.07	19.88	-26.64	12.00
Net Profit Growth (%)	32.39	182.61	21.66	-24.38	20.07
EPS Growth (%)	36.68	277.72	25.42	-21.99	50.65
Book Value Growth (%)	11.36	22.95	18.43	11.27	79.97

	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech	Sudeep Pharma
Price / Earnings	32.49	48.78	24.59	46.28	57.31
Price / Book Value	6.41	12.01	4.39	6.20	11.79
Dividend Yield (%)	0.20	0.18	0.40	0.61	0.16
EV/EBITDA	17.80	31.62	17.37	32.03	46.89
Market Cap (₹ Cr)	30,257.56	15,412.11	11,956.86	10,627.92	6,690.53

	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech	Sudeep Pharma
Debt to Equity	0.05	0.09	0.00	0.00	0.04
Short term debt to equity ratio	0.16	--	--	--	0.12
Current Ratio	1.43	2.09	5.21	7.39	3.09
Quick Ratio	0.82	1.37	3.85	5.46	2.02
Interest Coverage	10.36	26.41	148.49	1,386.30	30.94

	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech	Sudeep Pharma
Debtors to sales (%)	26.46	22.82	41.42	41.52	33.68
Asset Turnover	1.09	0.93	0.70	0.52	1.15
Receivable days	88.68	77.32	144.58	169.86	115.16
Inventory Days	84.11	80.83	96.67	97.92	96.15
Payable days	176.65	125.94	135.45	159.68	106.08
Cash Conversion Cycle	-3.86	32.22	105.80	108.11	105.23

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.